Worldquant Millennium Advisors LLC Acquires Shares of 414,845 DexCom, Inc. (NASDAQ:DXCM)

Worldquant Millennium Advisors LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 414,845 shares of the medical device company’s stock, valued at approximately $32,262,000. Worldquant Millennium Advisors LLC owned about 0.11% of DexCom at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Woodline Partners LP bought a new stake in DexCom during the fourth quarter worth about $63,338,000. Waters Parkerson & CO. LLC lifted its position in DexCom by 1.4% during the fourth quarter. Waters Parkerson & CO. LLC now owns 313,197 shares of the medical device company’s stock worth $24,357,000 after purchasing an additional 4,364 shares during the period. Triglav Skladi D.O.O. bought a new stake in DexCom during the fourth quarter worth about $1,439,000. Twinbeech Capital LP lifted its position in DexCom by 742.1% during the fourth quarter. Twinbeech Capital LP now owns 529,151 shares of the medical device company’s stock worth $41,152,000 after purchasing an additional 466,312 shares during the period. Finally, Two Sigma Advisers LP lifted its position in DexCom by 8.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,243,776 shares of the medical device company’s stock worth $96,728,000 after purchasing an additional 100,300 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares of the company’s stock, valued at approximately $26,183,401.02. This trade represents a 8.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $914,940.00. Following the completion of the sale, the executive vice president now directly owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This trade represents a 10.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock worth $4,734,384 in the last ninety days. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on DXCM. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, March 4th. Cfra Research raised shares of DexCom to a “hold” rating in a report on Friday, March 21st. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and increased their target price for the stock from $85.00 to $115.00 in a report on Monday, February 3rd. Mizuho began coverage on shares of DexCom in a report on Thursday, April 10th. They issued an “outperform” rating and a $85.00 target price for the company. Finally, Robert W. Baird dropped their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and an average target price of $98.11.

DexCom Trading Up 0.4%

NASDAQ DXCM opened at $87.34 on Wednesday. The stock has a market capitalization of $34.25 billion, a price-to-earnings ratio of 61.08, a PEG ratio of 2.30 and a beta of 1.43. DexCom, Inc. has a one year low of $57.52 and a one year high of $131.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The business’s fifty day moving average is $72.71 and its 200-day moving average is $77.87.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 30.14% and a net margin of 14.29%. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.32 earnings per share. Equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.